No joy for Ajovy: Teva's migraine drug can't find a win in meta-analysis versus Biohaven, AbbVie meds

When it comes to preventing chronic migraines, market-dominating injectables from Teva, Eli Lilly and Amgen are starting to feel the heat from formidable oral rivals. Looking to gain an early leg up, pharma companies have tried to pin their antibodies against up-and-coming migraine meds in an effort to woo over patients and doctors.

Except a new analysis from Teva pitting its long-acting injectable Ajovy against oral foes from Biohaven Pharmaceuticals and AbbVie doesn’t appear to separate the drug from the pack as the company likely hoped.